BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals' stock has been impacted by several key events. In Q2 2025, the company reported strong earnings driven by ORLADEYO demand and reaffirmed its full-year revenue outlook. The BCX10013 program was discontinued due to inadequate activity. BioCryst sold its European business to Neopharmed Gentili to strengthen its financial position. In Q3 2025, the company reported an EPS miss but raised its ORLADEYO revenue guidance. Jon P. Stonehouse announced a leadership change, with Charles K. Gayer becoming the new CEO. As of November 5, 2025, the stock had decreased by 5.6% year-to-date.

Demand seasonality for BioCryst Pharmaceuticals is primarily observed with its influenza treatment, RAPIVAB, due to the seasonal nature of influenza. ORLADEYO, which treats a rare disease, typically exhibits more consistent demand throughout the year. Specific detailed information on demand seasonality for all of BioCryst's products and services is not readily available.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics for rare and serious diseases. The company operates in the Healthcare sector, specifically in the Biotechnology & Medical Research industry, and utilizes structure-guided drug design. Its major marketed products include ORLADEYO® (berotralstat) for hereditary angioedema (HAE) and RAPIVAB® (peramivir injection) for acute uncomplicated influenza. BioCryst also has a pipeline of investigational candidates, including BCX10013, BCX17725, and Avoralstat, as well as Oral C5 Inhibitor and Oral C2 Inhibitor.

BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina, United States. The company has a global presence, with ORLADEYO having approvals and reimbursement in Europe and Latin America, and RAPIVAB approved in the United States, Japan, Korea, and China.

BioCryst Pharmaceuticals has maintained a positive brand reputation, particularly within the investment community, receiving a consensus rating of "Moderate Buy" from analysts. Analyst and management sentiment during recent earnings calls has been optimistic. The discontinuation of the BCX10013 program was a setback but was mitigated by the company's overall positive financial performance and pipeline advancements.

BioCryst Pharmaceuticals is primarily owned by institutional shareholders, who hold approximately 92.21% of the stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Deerfield Management Company, L.P. Baker Bros Advisors LP is the largest individual shareholder, owning 10.23% of the company. Insiders own about 1.76% of the company's stock.